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Direct-to-consumer (DTC) genetic tests have aroused controversy. Critics have argued many of
the tests are not backed by scientific evidence, misguide their customers and should be regu-
lated more stringently. Proponents suggest that finding out genetic susceptibilities for diseases
could encourage healthier behaviours and makes the results of genetics research available to the
public. This paper reviews the state of play in DTC genetic testing, focusing on tests identi-
fying susceptibilities for lifestyle-related diseases. It will start with mapping the market for the
tests. The paper will review (1) research on the content of the online marketing of DTC tests,
(2) studies on the effects of DTC genetic tests on customers and (3) academic and policy
proposals on how to regulate the tests. Current studies suggest that the marketing of DTC
genetic tests often exaggerates their predictive powers, which could misguide consumers.
However, research indicates that the tests do not seem to have major negative effects (worry
and confusion) but neither do they engender positive effects (lifestyle change) on current users.
Research on regulation of the tests has most commonly suggested regulating the marketing
claims of the companies. In conclusion, the risks and benefits of DTC genetic tests are less
significant than what has been predicted by critics and proponents, which will be argued
reflects broader historical trends transforming health and medicine.
Direct-to-consumer genetic testing: Nutrigenetics
Direct-to-consumer (DTC) genetic tests are sold directly
to the consumer, without the mediation of a health-
care professional, typically via the Internet. The tests have
attracted both positive and negative publicity. In 2008, the
Time Magazine named the DTC whole genome scan sold by
the company 23andMe the ‘Innovation of the Year.’ How-
ever, it has been noted that the scientific evidence supporting
the association between a gene variant and a disease or pre-
ventive advice for many of the DTC genetic tests is lim-
ited(1). For this reason, the tests have been criticised for
misleading the public and for potentially making individuals
unduly anxious about their future health(2,3). The companies
have argued that they may encourage healthy lifestyle
and are making the results of investments in genomic
research available to ordinary individuals.
Customers purchasing DTC genetic tests usually send a
saliva sample to a company and receive their results via
mail or uploaded onto an online account. Some DTC
genetic testing companies may identify just one gene var-
iant, whereas so-called ‘whole genome scans’ frequently
cover several hundred gene variants. Companies test for a
variety of genes associated with susceptibility for diseases,
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traits, ancestry and paternity. Some companies sell ‘nutri-
genetic’ tests, which identify individuals’ susceptibilities
for lifestyle-related diseases, such as CVD and various
cancers, and provide advice on nutrition and supplements.
Nevertheless, companies, which do not market their tests
as nutrigenetic, also offer dietary advice in conjunction
with tests that identify susceptibilities for lifestyle-related
diseases. DTC genetic testing websites often link to
scientific articles and may contain interactive features,
such as user forums. In 2012, the typical price for the tests
was several hundred US dollars. In 2011, 23andMe stated
that it had sold 100 000 whole genome scans(4).
A 2008 review identified twenty-six ‘recent’ companies
marketing DTC genetic tests, of which all but one (Acu
Gen, offering a fetal gender test) offered health or lifestyle
related tests (e.g. nutrigenetic tests or tests for disease
susceptibility or anti-ageing)(5). To get a sense of the sta-
bility of the market, I reviewed the websites in 2012 to see
how many were still in operation. Twelve or nearly half of
the companies continued to offer DTC genetic tests. Of the
remaining fourteen companies, seven had ceased func-
tioning, four offered genetic tests only via a physician and
three sold genetic tests not related to health, i.e. paternity
and fetal gender tests (see Table 1). These figures indicate
not only a fair amount of fluctuation in the market but also
the emergence of several companies that have operated for
some time (there are also new companies on the market
that did not operate in 2008). Nevertheless, the long-term
future and shape of the market is less clear, as most of the
companies are small and change frequently.
This paper will review the state of play in the marketing of
DTC genetic tests, focusing on tests identifying suscept-
ibilities for lifestyle-related diseases. First, the article will
review research on the content of the online marketing and
sales portals for the tests. Second, I will discuss research on
the experiences of customers of DTC genetic testing com-
panies as well as experiences of genetic susceptibility testing
more generally. Third, I will review policy and academic
proposals on how to regulate DTC genetic tests.
In conclusion, the paper argues that DTC genetic tests
embody several historical trends, which are transforming
health and medicine. As such, their risks and benefits are
less significant than what has been predicted by critics and
proponents.
Table 1. (a) Companies which offered health or lifestyle related direct-to-consumer (DTC) genetic tests in 2008(5) and continued to do so (as of
2012). (b) Companies which were offering health or lifestyle related DTC genetic tests in 2008 but no longer offered health-related DTC genetic
tests (as of 2012)
Name of the company Types of health or lifestyle related DTC genetic tests offered
(a)
23andMe Whole genome test
Genetic Health Variety of tests, including a nutrigenetic test, UK
Geneticom Several genetic tests, including tests for haemochromatosis and
thrombophilia, unclear delivery, German
Genosense (Christos Pampakerides) Several genetic screens, including a nutrigenetic screen, Cypriot
Graceful Earth Genetic test for Alzheimer’s disease
Health Tests Direct Variety of tests, including ApoA1, unclear if DNA or protein tests offered
Health Check USA Variety of tests, including a genetic test for haemochromatosis,
free genetic counselling offered through Kimball Genetics
Holistic Health Variety of tests, including a nutrigenetic test, unclear delivery
Kimball Genetics Variety of tests, including thrombophilia and ApoE testing, order
through telephone after a discussion with a genetic counsellor
Medichecks Variety of tests, including genetic tests for thrombophilia and
breast cancer, breast cancer test via physician only, UK
Quixtar/Interleukin Variety of tests, including a nutrigenetic test
Suracell Anti-ageing genetic tests, Italian
(b)
Acu-Gen Biolab Defunct, used to only offer a fetal gender test
Consumer Genetics Only offers a fetal gender test currently
Cygene Direct Defunct
DeCODE Offers whole genome test via physician only
Dermagenetics Offers anti-ageing DNA tests via ‘aesthetic physicians’ only
DNA Direct Offers genetic tests via physician only
G-Nostics Defunct, offered a genetic test for nicotine addiction
Genelex Only offers paternity tests currently
Medigenomics Only offers paternity tests currently, other genetic
tests for industry, German
Mygenome Defunct (website still exists but not operational)
Navigenics Whole genome test via physician only
Salugen Defunct, offered nutrigenetic tests
Sciona Defunct, offered nutrigenetic tests
Smart Genetics Defunct
54 P. Saukko
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
Content of marketing websites
One of the main concerns about DTC genetic tests is
that they may ‘misguide’ the public by making overstated
claims(2,3). There are several studies that have investigated
the content of DTC genetic testing companies, marketing
websites and their test results. In 2006, the US Government
Accountability Office published a report based on exam-
ining the results its investigators received from four nutri-
genetic testing companies. The investigators concluded
that even if the tests contained disclaimers that they were
not intended to diagnose disease, the test results predicted
the consumers were at risk of various diseases. To hedge
their claims the companies stated the consumers ‘may be’
at risk. The investigators also criticised the companies for
selling overpriced supplements in conjunction with the
tests and for making scientifically unsound promises that
the supplements could ‘repair DNA damage’(3).
In 2010, the Government Accountability Office investi-
gated further four DTC genetic testing companies, includ-
ing those offering whole genome scans. Its investigators
noted that the different companies provided the same
consumers (i.e. the same DNA sample was sent to several
companies) very different risk profiles for the conditions
they claimed to test, such as prostate cancer and hyper-
tension. The Government Accountability Office report also
expressed concern about statements in the companies’
results that indicated that a consumer had a high risk of
cancer. The investigators pointed out that while the com-
panies advertised they would offer further expert advice
they often could not offer such advice(2).
Several academic studies have examined the content of
DTC genetic testing websites. Lachance et al.(6) analysed
twenty-nine such websites and observed that while nearly
all (90%) stated the benefits of the tests only half (55%)
presented limitations of the tests. Further, the authors noted
that only slightly over a third (38%) of the sites supported
their claims with scientific evidence and, as a consequence,
did not often distinguish between tests in a situation, where
the clinical validity of the tests varies significantly, i.e. the
strength of the association between a gene variant and a
disease may be more strongly or weakly supported by
evidence. Other studies have presented similar findings.
Lewis et al.(7) found that only seven out of the twenty-five
DTC genetic testing websites analysed complied with most
of the transparency requirements outlined by the American
Society for Human Genetics, and less than half (ten out of
twenty-five) offered information on the predictive value of
the genetic markers being tested. Similarly, Singleton
et al.(8) observed that while many (74%) of the twenty-
three DTC genetic testing websites analysed contained
disclaimers about the clinical usage of the tests (i.e. that
they are not intended to diagnose disease), only a third
(30%) discussed current limitations of the predictive abil-
ity of the genetic tests. An analysis of sixty-four organi-
sations promoting (even if not always selling)
nutrigenomic tests noted that only 13% presented infor-
mation on the limitations of the tests and current science
behind them(9).
Different companies fared differently in terms of infor-
mative content. Both Lachance et al.(6) and Lewis et al.(7)
found that whole genome testing companies were more
likely to discuss the limitations of the tests(6,7). Whole
genome test sites, often containing illustrative graphs, also
fared better in terms of readability of the sites, in a situa-
tion where most sites were difficult to navigate
and understand, with only 7% using mostly common
language(6). However, even the companies, which provided
evidence of the predictive value of the test, did not often
discuss how little such predictions mattered in the overall
puzzle where multiple genetic factors (most of which are
yet unknown) and environmental factors interact to pro-
duce lifestyle-related diseases(7).
Research has also identified a few common ways in
which DTC genetic testing companies frame their services.
Liu and Pearson observed that 90% of the forty-six com-
panies marketing health-related genetic tests online used
the emotional appeal of ‘empowerment’ and being in
control(10); other studies have made similar observa-
tions(11,12). Based on a qualitative analysis of DTC genetic
testing websites, Harvey noted that the discourse on
empowerment resonates with the current public health
ethos, which emphasises patient’s personal responsibility
to enhance their health and their ability and entitlement to
make choices about their healthcare(11). In another quali-
tative study of DTC genetic testing websites, Nordgren and
Juengst noted that the companies framed their customers as
having the ‘right to know’ their genome, drawing on the
‘open source’ discourse, which emphasises individuals’
right to openly access and share information(13). These
results indicate that the companies mobilise the current
anti-paternalistic sentiment, according to which individuals
should have both the privilege and duty to take care of
their own health.
The second most common emotional appeal, after
empowerment, on DTC genetic testing websites identified
by Liu and Pearson was ‘warmth,’ used in 60% of the
sites(10). Einsiedel and Geransar observed that the twenty-
two DTC genetic testing websites analysed also frequently
employed ‘credibility markers’ to engender trust in the
service, such as emphasising the professional credentials of
the management team or laboratory accreditation. They
also found that nineteen out of twenty-two company web-
sites engendered credibility by making the site easy to
navigate(14). Lachance, however, found the websites hard
to navigate; only ten out of thirty-four companies provid-
ing a search-engine for the site(6).
Several studies have examined whether DTC genetic
testing companies offer advice by a physician or genetic
counsellor. This is somewhat complicated, as the compa-
nies frequently change between offering their services
direct or via a physician or other professional, such as a
nutritionist. In 2003, Gollust et al. observed that of the
fourteen companies marketing health-related genetic test-
ing on the Internet seven offered them direct, and out of
those seven, three indicated that they could provide their
customers access to a physician’s advice if requested.
Companies that provided the tests results via a physician
tended to offer more tests with significant implications,
such as supplementary newborn screening(15). Similarly,
Geransar and Einsiedel noted that of the twenty-four
companies advertising genetic tests directly to consumers
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those that required physician mediation typically offered
risk assessment and diagnostic tests, whereas companies
selling the tests direct over the Internet offered ‘enhance-
ment’ test, such as nutrigenetic tests(16). A recent analysis
of the content of twenty-nine DTC genetic testing websites
found that four (14%) provided an opportunity to talk to a
healthcare professional before the test and eight (28%)
offered such an opportunity afterwards(6).
Studies indicate that genetic tests with potentially sig-
nificant implications, such as newborn screening tests or
tests for predisposition to breast cancer, are typically
offered via physician, whereas tests with less significant
impact, such as nutrigenetic tests, are offered direct.
However, similar tests, such as whole genome scans, can
be offered both direct (23andMe) or via a physician
(Navigenics). Further, when we analysed the websites of
nine nutrigenetic testing companies we noted that some of
them framed their services as medical (using clinical lan-
guage and images, such as stethoscopes) and others as
lifestyle products (presenting images of, for example,
glistening fruits and vegetables or a spa-like setting)(12).
Thus, while sometimes the way in which the tests are sold
and marketed indicate the seriousness of the test, at other
times such differences are simply rhetorical, reflecting the
chosen marketing strategy of the company.
On the whole, the DTC genetic testing companies seem
to oversell their services, with a substantial portion not
appropriately disclosing the limits of the science behind
the tests. There were differences between companies,
whole genome testing services faring better, but hardly any
companies fully discussed the limited predictive power of
the tests, in a situation where new genetic risk factors are
continuously being discovered and their interaction with
multiple environmental factors mostly remains an unre-
solved puzzle. The companies mobilised a sense of
empowerment, expertise and warmth to market their tests,
typical strategies in marketing, and online marketing
especially, to enhance customers’ sense of agency as well
as pleasure and positivity associated with the service(17).
Some companies framed their tests more as medical and
others more as lifestyle products, of those companies sell-
ing the tests directly online only a minority provided
advice by a healthcare professional for those seeking more
assistance.
While there was variation between companies, the cur-
rent research indicates that the information provided by
DTC genetic testing companies was often potentially
misleading.
User experiences of direct-to-consumer genetic tests
The main concern about DTC genetic testing has, indeed,
been that it may misguide consumers and worry them,
i.e. make them unnecessarily anxious about health risks
or wrongly reassure them about lack of risk(2,3). The ben-
efit of genetic testing for lifestyle-related diseases, sug-
gested by the commercial companies as well as public
policy(18), is that it could encourage individuals to change
their behaviour.
Several recent studies on how users respond to whole
genome scans have observed that they seem to have no
major negative or positive effects or engender major mis-
understandings. A before and after study on 2037 con-
sumers who had been offered Navigenics’ Health Compass
at a reduced price reported no changes in anxiety, fat
intake, exercise levels or rate of use of screening three
months after the test. Only 10% of the consumers had
consulted a genetic counsellor, which was offered free of
charge, but 26% had shared their results with a physi-
cian(19). In a trial (n 345) comparing the responses of those
patients who had received usual care or usual care plus a
modified version of the Navigenics test, James et al.
reported increased initial perception of risk for most con-
ditions and lower perceived risk for prostate cancer.
However, at one-year follow-up the difference had dis-
appeared, further supporting a null hypothesis for the
effects of DTC genetic testing(20).
Such findings are unsurprising against studies that have
examined psychological and behavioural effects of genetic
susceptibility testing in clinical settings and have fre-
quently found modest or no effects. A recent review of
trials on whether genetic tests for susceptibility to lung
cancer encourage smoking cessation concluded that the
findings did not suggest that genetic information would add
value to existing smoking cessation programmes. How-
ever, there were positive effects among some subgroups.
The few studies on genetic susceptibility for obesity and
heart disease have found that providing genetic informa-
tion does not increase fatalism, i.e. sense that nothing can
be done to prevent the condition, but does not encourage
lifestyle change either(21). There exist some smaller studies
that have indicated that nutrigenetic information may
motivate weight management or is perceived as more
useful than ordinary dietary advice, but in the absence of
further studies to corroborate these findings it is hard to
assess their meaning(22,23).
Qualitative studies, however, have indicated that there
may be subgroups, who may take genetic susceptibility
testing more seriously. Studies on patients’ experiences of
inherited susceptibility for breast cancer, heart disease,
haemochromatosis and deep vein thrombosis have
observed that genetic or familial risk information is con-
sidered salient, if individuals already perceive themselves
at risk. Such a sense of vulnerability may derive from
having personally experienced the disease, having family
members who have developed the disease or have other
risk factors, such as high cholesterol(24–28). Such observa-
tions have been corroborated by a recent online survey of
3167 customers of whole genome testing companies.
Kaufman et al. found that those customers, who had a
personal or a family history of a disease or poorer self-
reported health, were more likely to report that they would
consider lifestyle changes(29). Thus, while DTC genetic
tests seem not to have major negative or positive effects on
their customers in general, there may be subgroups, who
may already perceive themselves at risk and take the
results more seriously, either in a positive or possibly
negative way.
Another concern has been that customers misunderstand
DTC genetic tests and get unduly worried about their
health or consider themselves not to be at risk. In the
Multiplex study, which offered patients a genetic test,
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which included fifteen gene variants associated with eight
lifestyle-related diseases participants’ understanding was
good. Of the 199 participants 80% correctly recalled their
risk status for the eight conditions, and they did not inter-
pret the results deterministically, i.e. in terms of genes
being major determinants of disease. Participants did not
report overly negative or positive emotions. Those with
least deterministic views were better educated and
white(30). While the findings are reassuring, it should be
borne in mind that the information provided by the Multi-
plex study may not be comparable to information provided
by DTC genetic testing companies. However, similar
findings have also been obtained in a McGowan et al. qua-
litative study of twenty-three customers of whole genome
testing companies. The customers were enthusiastic about
the science, but aware of the limitations of the test(31).
Studies have also explored individuals’ motivations for
purchasing DTC genetic tests. Su et al.(32) analysed blogs
and user-forum discussions of customers of DTC genetic
testing companies and found that individuals’ were moti-
vated to purchase the tests to learn about their health.
However, they were also driven by other motivations, such
as curiosity, interest in genealogy, interest in participating
in research and entertainment. McGowan et al. also found
that most commonly individuals were motivated to pur-
chase the test to learn about their health. However, more
than a half of the customers had a professional interest in
genetics and wanted to be on the ‘vanguard’ of adopting
this new technology(31). Individuals who chose to partici-
pate in the Multiplex study and have the genetic scan did
not hold deterministic views about genes but believed
genetic information to be valuable and were confident they
could understand it(30). Furthermore, individuals who know
about and are interested in DTC genetic testing at the
moment seem an exclusive and small group. A US popu-
lation-based survey conducted in 2006 found that 14% of
individuals were aware of nutrigenomic tests, and those
aware were predominantly well-educated and white(33,34).
A UK survey in 2008 found that 13% were aware of per-
sonal genome testing. Incidentally, the customers of DTC
genetic testing, including the participants in the reviewed
studies, tend to be white, well-educated and wealthier than
average(19,20,35).
On the whole, based on current research DTC genetic
testing seems not to engender major negative or positive
effects, nor does it seem to lead to major misunderstand-
ings about genetic determinism. There are at least three
possible explanations to this. First, the early adopters of
DTC genetic tests tend to be well-educated and privileged,
hence their understanding could be good and psychological
reactions muted. It has been argued that if such tests would
be adopted more widely, they could create more mis-
understandings and worry(36). Second, risk information
about lifestyle-related diseases rarely engenders significant
behavioural or psychological reactions even in clinical
settings. In this respect, online genetic tests join many
other lifestyle interventions, the positive and negative
impacts of which are often limited(37). Third, it is con-
ceivable that consumers of DTC genetic tests do not per-
ceive them as medical services but more as consumer
products marketed with health claims. Consumers typically
interpret commercial messages with a pinch of salt; also
health claims associated with food products are not
taken at face value, but their credibility varies according to
product, type of claim, cultural context and individuals’
background(38). Furthermore, although users of DTC
genetic tests frequently purchased the service to learn
about their health, they also had other motives, such as
curiosity and interest in science.
Regulation of the tests
Companies have been able to sell genetic tests online
due to a loophole in regulation, which does not require in-
house or ‘homebrew’ laboratory tests to undergo
pre-market review. Ever since the first tests were sold on
the Internet in the early 2000 policy-makers in the UK,
USA and elsewhere have discussed how to regulate
them(5).
The discussion on whether and how to regulate DTC
genetic tests has revolved around their validity and the
benefits and harms the tests might engender. The analytical
validity of the tests, focusing on whether the test accurately
identifies the gene variant it is purported to identify, is
regulated by laboratory regulation, such as them Clinical
Laboratory Improvement Amendment accreditation. More
challenging questions are clinical validity, i.e. whether the
gene variant is associated with a specific disease and clin-
ical utility, i.e. whether identifying the association has any
health benefits. The majority of genetic tests offered DTC
have limited clinical validity, because the discovered
associations between a gene variant and a health condition,
such as obesity, are only a minor part of the puzzle of
interacting genetic and environmental factors, which
account for an individual’s body weight. As discussed in
the previous section, the clinical utility, for example, the
ability of these tests to encourage healthy behaviour, is
also debatable.
However, the validity, utility and risks of the tests vary.
Some single gene tests, such as the tests for a genetic
predisposition to breast cancer (BRCA1 and BRCA2), have
strong clinical validity (associated with 70–80% lifetime
risk of breast cancer) but are also associated with sig-
nificant psychological implications both for the individuals
and their family members. On the contrary, nutrigenetic
tests often include gene variants with tenuous clinical
validity(1), but based on research on effects of DTC genetic
testing, they do not seem to cause significant psychological
harm. For this reason, from early on regulators have sug-
gested different genetic tests might need to be regulated
differently.
Already in 2002 the UK Human Genetics Commission
sought to distinguish between genetic tests with ‘high,’
‘intermediate’ and ‘low’ impact(39). Regulation of genetic
tests has also revolved around how to categorize the tests.
In Europe, genetic tests fall under the purview of the
in vitro diagnostic medical devices directive. Discussions
around the directive have focused on whether genetic tests,
or which genetic tests, are considered medical devices.
Further, as noted by a recent background document for the
European Society for Human Genetics, the question has
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been whether genetic tests would fall under the risk cate-
gory ‘A’, which would require pre-market review. Pre-
market review for diagnostic devices is far less stringent
than for pharmaceuticals but, nevertheless, requires sub-
mission of clinical studies to gain approval and regulates
truthfulness in labelling and promotional materials(40).
While the European Union regulation remains unclear,
several member states, such as France and Germany,
require that genetic tests are carried out by a doctor(41).
The UK allows the provision of DTC genetic testing. In the
USA, there has been a debate over whether DTC genetic
tests fall under the jurisdiction of the Food and Drug
Administration. In 2006, in hearings in the US senate
Committee on Ageing, after the condemning the Govern-
ment Accountability Office report on the results of DTC
genetic tests, Steve Gutman from the Food and Drug
Administration concluded that the agency was working on
establishing whether DTC genetic tests were medical
devices and how they would be regulated(42). In 2011, the
Secretary’s Advisory Committee on Genetics, Health and
Society made a number of recommendations concerning
oversight of DTC genetic tests, review of genetic testing
claims and promotional materials and their clinical valid-
ity(43). In March 2011, the Food and Drug Administration
held a meeting in which it indicated that it intended to
regulate DTC genetic tests(44), and the agency sent letters
to DTC genetic testing companies requesting they submit
their products and services to pre-market review. Even if
the Food and Drug Administration actions indicated that
the Agency was intending to regulate the DTC testing
market, it still was not clear in 2012 what shape this reg-
ulation would take.
As noted by Wright and Zimmern, there are, in principle,
three ways of responding to the regulatory challenge posed
by DTC genetic tests. The libertarian option would be to
allow the tests to be marketed without restrictions, as they
do not cause direct harm (unlike pharmaceuticals). The
conservative option would be not to allow any tests to be
marketed without proven clinical utility and clinical support,
because of potential harms, such as psychological distress
and misguidance due to erroneous clinical information. The
intermediate position would be to regulate the safety
and accuracy of the tests and the validity of the marketing
claims of the tests(45). Many commentators agree that as
‘a minimum’ the claims made by DTC genetic testing com-
panies should be reviewed and regulated(46).
The likely outcome of deliberations on regulation will
be a solution close to the intermediate position outlined
earlier, i.e. the basic safety and accuracy of the tests and
their marketing claims will be regulated. Such a develop-
ment is likely as there has been no indication that the tests
produce major harms, a political compromise is appealing
and the neo-liberal historical political climate does not
favour prohibitive regulation in general.
Discussion
Selling genetic tests on the Internet may seem an extra-
ordinary idea. However, rather than being a unique phe-
nomenon, the trends identified by current research indicate
the technology is associated with general, historical
developments transforming health and medicine.
In the early twenty-first century the notion of science
and medicine as autonomous and authoritative sources of
‘truth’ is waning. This is witnessed by, for example, the
fact that the lay public increasingly questions science, as
happened in the controversy over GM crops. The authority
of science is also challenged by its increasing enmeshment
with commercial interests(47). These historical develop-
ments are reflected in current research, which suggests that
DTC genetic testing companies exaggerate the predictive
powers of the tests, even if they also hedge their claims.
The marketing of DTC genetic tests mobilises the authority
of science to sell the tests, but it also erodes faith in sci-
ence by using obviously commercial advertising rhetoric
and, at least in some cases, by presenting information on
the limits of the science behind the services.
The traditional notion of the patient, who submits to
doctor’s authority, is also giving way to ‘expert patients’,
who want to be treated as equal partners in making deci-
sions about their health and health-care and consult the
Internet to acquire information on and manage their
health(48). Simultaneously, health is becoming the respon-
sibility of individuals rather than primarily the health-care
system. However, theorists of the information society point
out that the proliferation of commercial and other infor-
mation inviting audience engagement produces individuals,
who may be fascinated by the ubiquitous media and other
messages but, at a deeper level, become indifferent to
them(49). Research on customers of DTC genetic tests
indicate that they seem, indeed, to behave as expert
patients, capable of acquiring and evaluating health infor-
mation on their own, as they do not end up anxious or
confused by the marketing information. However, the same
lack of response applies to the motivational appeal of the
tests, customers by and large not changing their health
behaviours based on the results. The muted response of the
customers mirrors the contradictions of information
society, whereby individuals are increasingly engaged with
information but, at the same time, remain disaffected by it.
Nevertheless, these observations should be interpreted in
light of the fact that the current users of DTC genetic tests
tend to be educated, wealthy and white.
In a further historical development states are losing
control over both lay and commercial activities due to
globalization, liberalization and the Internet(50). These
developments make it increasingly difficult for states to
control a phenomenon, such as DTC genetic testing, which
incorporates new technology and commerce that crosses
borders. Further, in the current political climate, favouring
liberalization of the markets and facilitation of commerce,
it is not likely that many governments or intergovern-
mental organizations, such as the European Union, will
regulate DTC genetic tests in the strictest manner.
Critics have accused DTC genetic testing companies for
not living up to expectations of traditional medicine,
i.e. provide evidence-based serious information with potent
positive and negative effects via an accredited profes-
sional. However, as I, and others, have suggested these
tests are novel phenomena not necessarily obeying the
logic of conventional medicine(12,51). While the tests are
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marketed and consumed as health products, their marketing
follows the hyperbole of consumer advertising; the current
consumers of the tests do not seem to be majorly affected
by the service, and the regulation of the tests is most
likely to focus on consumer regulation, i.e. regulating the
marketing claims. As such, the DTC genetic tests reflect
the transformations in medicine in terms of erosion of the
authority of scientific truth, individuals’ increasing
engagement with and indifference towards health and other
information and diminishing of state authority and liberal-
ization. DTC genetic tests are only one example of health
products embodying these transformations; others include,
for example, food-products associated with health claims.
Health claims are also associated with varied scientific
evidence, have been accused of misleading marketing,
provoked varied consumer credibility, and policy-makers
have responded to their challenge by regulating marketing
somewhat differently in different countries.
The concern, rising from interpreting DTC genetic tests
in traditional medical terms, that the tests harm individual
consumers seem, based on current research, misdirected.
Rather, the problem with DTC genetic tests is that they do
not address major, contemporary public health issues
and may, together with similar innovations, mask these
real concerns. The major contemporary health issue is
global health inequality, brought about by poverty, life-
style-related diseases, old and new infectious diseases and
perinatal conditions, which account for poor health and
starkly short life expectancy in many developing countries.
The major challenge facing developed countries is the
epidemic in lifestyle-related diseases, which are generated
by complex social processes affecting our diet and exercise
and are significantly more prevalent among deprived indi-
viduals and regions. These problems cannot be resolved
by innovative health products targeted at wealthy niche
markets.
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